
ETON Stock Forecast & Price Target
ETON Analyst Ratings
Bulls say
Eton Pharmaceuticals is positioned for growth, with a successful launch of a new product and a potential licensing deal for a new treatment. However, limited resources and the need for continuous fundraising could impact the company's valuation. Management's conservative approach to guidance is viewed positively, with a Buy rating and a 12-month price target of $65.00 per share, indicating potential for future growth and success.
Bears say
Eton Pharmaceuticals is experiencing a surge in growth, as evidenced by its largest beat and raise in company history due to the rapid ramp-up of its flagship product HEMANGEOL and successful conversion to a single-specialty pharmacy model. However, with the shift to converting off-label adult propranolol use and the development of ASN-001, a potential top product, there are concerns about cannibalization of HEMANGEOL and the need for further commercial build. Additionally, with licensing revenue fluctuating and potential approval for a new pediatric formulation in the pipeline, there may be some instability in the short term, leading to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
ETON Analyst Forecast & Price Prediction
Start investing in ETON
Order type
Buy in
Order amount
Est. shares
0 shares